A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors

Phase 1 & 2

Waitlist Available

Research Sponsored by Haihe Biopharma Co., Ltd.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up c1d1,pre-dose,15min,30min,1h,2h,3h,4h,6h,8h,12h;c1d2, pre-dose and 24h; c1d7,c1d10, pre-dose.c1d15 at pre-dose,15min,30min,1h,2h,3h,4h,6h,8h,12h, c1d16 pre-dose and 24h,c1d22 pre-dose,and c2d1,c3d1,c5d1,c7d1,c9d1 pre-dose.

Awards & highlights

No Placebo-Only Group

Summary

This trial tests HH2710, a new drug for patients with advanced tumors. It works by blocking proteins that help cancer cells grow, potentially slowing or stopping the cancer.

Eligible Conditions

Advanced Tumors
Erdheim-Chester Disease
Skin Cancer
Melanoma
Non-Small Cell Lung Cancer
RAS/RAF/MEK/ERK Mutated Tumors

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ c1d1,pre-dose,15min,30min,1h,2h,3h,4h,6h,8h,12h;c1d2, pre-dose and 24h; c1d7,c1d10, pre-dose.c1d15 at pre-dose,15min,30min,1h,2h,3h,4h,6h,8h,12h, c1d16 pre-dose and 24h,c1d22 pre-dose,and c2d1,c3d1,c5d1,c7d1,c9d1 pre-dose.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~c1d1,pre-dose,15min,30min,1h,2h,3h,4h,6h,8h,12h;c1d2, pre-dose and 24h; c1d7,c1d10, pre-dose.c1d15 at pre-dose,15min,30min,1h,2h,3h,4h,6h,8h,12h, c1d16 pre-dose and 24h,c1d22 pre-dose,and c2d1,c3d1,c5d1,c7d1,c9d1 pre-dose.

This trial's timeline: 3 weeks for screening, Varies for treatment, and c1d1,pre-dose,15min,30min,1h,2h,3h,4h,6h,8h,12h;c1d2, pre-dose and 24h; c1d7,c1d10, pre-dose.c1d15 at pre-dose,15min,30min,1h,2h,3h,4h,6h,8h,12h, c1d16 pre-dose and 24h,c1d22 pre-dose,and c2d1,c3d1,c5d1,c7d1,c9d1 pre-dose. for reporting.